Evaluation of an Antisense Oligonucleotide Targeting CAG Repeats: A Patient-Customized Therapy Study for Huntington’s Disease

Evaluation of an Antisense Oligonucleotide Targeting CAG Repeats: A Patient-Customized Therapy Study for Huntington’s Disease

Huntington’s disease is a genetic disorder characterized by progressive neuronal cell damage in some areas of the brain; symptoms are commonly associated with chorea, rigidity and dystonia. The symptoms in Huntington’s Disease are caused by a pathological increase in the number of Cytokine-Adenine-G...

Full description

Saved in:

Bibliographic Details
Main Authors:	Sergio Adrian Ocampo-Ortega, Vivany Maydel Sierra-Sanchez, Citlali Margarita Blancas-Napoles, Asdrúbal González-Carteño, Elvia Mera-Jiménez, Martha Edith Macías-Pérez, Adriana Hernandez-Guerra, Rodrigo Romero-Nava, Fengyang Huang, Enrique Hong, Santiago Villafaña
Format:	Article
Language:	English
Published:	MDPI AG 2024-12-01
Series:	Life
Subjects:	CAG cluster Huntington’s disease Huntingtin long antisense oligonucleotide
Online Access:	https://www.mdpi.com/2075-1729/14/12/1607
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Application of antisense oligonucleotide drugs in amyotrophic lateral sclerosis and Huntington’s disease
by: Kaili Ou, et al.
Published: (2025-01-01)

Antisense oligonucleotides for the arterial hypertension mechanisms study and therapy
by: L. O. Klimov, et al.
Published: (2018-04-01)

Clinical Applications of Antisense Oligonucleotides in Cancer: A Focus on Glioblastoma
by: Alexandre Khuu, et al.
Published: (2024-11-01)

In vivo efficacy and safety of systemically administered serinol nucleic acid-modified antisense oligonucleotides in mouse kidney
by: Toshiki Tsuboi, et al.
Published: (2025-03-01)

Multispanning membrane protein SIDT2 increases knockdown activity of gapmer antisense oligonucleotides
by: Kohshi Kusumoto, et al.
Published: (2025-01-01)

Personalized allele-specific antisense oligonucleotides for GNAO1-neurodevelopmental disorder
by: Inna Shomer, et al.
Published: (2025-03-01)

Changes induced in mouse lipid metabolism by simultaneous impact of antisense oligonucleotide derivatives to <i>apoB</i>, <i>PCSK9</i>, and <i>apoCIII</i> mRNAs
by: S. I. Oshevski, et al.
Published: (2020-01-01)

Exploring precision therapeutics: computational design of antisense oligonucleotides targeting AXL gene transcripts in multiple sclerosis treatment management
by: Bhargav Shreevatsa, et al.
Published: (2025-02-01)

Characterizing the plasma protein binding profiles of chemistry diversified antisense oligonucleotides in human and mouse plasma using an ultrafiltration method
by: Cassandra Yun, et al.
Published: (2025-01-01)

The N17 domain of huntingtin as a multifaceted player in Huntington’s disease
by: Hyunju Cho
Published: (2025-01-01)

Pathogenetic therapeutic approaches for endocrine diseases based on antisense oligonucleotides and RNA-interference
by: Olga Golounina, et al.
Published: (2025-01-01)

A novel metal‐organic framework encapsulated iridium oxide nanozyme enhanced antisense oligonucleotide combo for osteoarthritis synergistic therapy
by: Shuqi Wu, et al.
Published: (2024-12-01)

Treatment with Tau fibrils impact Huntington's disease-related phenotypes in cell and mouse models
by: Shireen Salem, et al.
Published: (2024-11-01)

Unveiling sequence-agnostic mixed-chemical modification patterns for splice-switching oligonucleotides using the NATURA platform
by: Tommaso Tabaglio, et al.
Published: (2025-03-01)

UBL3 Interacts with PolyQ-Expanded Huntingtin Fragments and Modifies Their Intracellular Sorting
by: Soho Oyama, et al.
Published: (2024-10-01)

Extracellular vesicle mimetics as delivery vehicles for oligonucleotide-based therapeutics and plasmid DNA
by: Anastasiya Oshchepkova, et al.
Published: (2024-10-01)

Oligonucleotides as a Novel Therapeutic Approach: An Innovative Area for Drug Delivery in Neurological Disorders
by: Yasir Qasim Almajidi, et al.
Published: (2025-01-01)

Halloysite clay nanotubes as platforms for loading of aptamers and antisense oligonucleotides
by: Maria Rita Caruso, et al.
Published: (2025-03-01)

Discovery and characterization of stereodefined PMO-gapmers targeting tau
by: Kunihiko Kanatsu, et al.
Published: (2025-03-01)

Effective inhibition of dengue virus replication using 3′UTR-targeted Vivo-Morpholinos
by: Mengwei Niu, et al.
Published: (2024-11-01)

Landscape of antisense genes in the human genome and identification of new human hepatic antisense RNAs by long-read sequencing
by: Juan Jose Rojo-Carrillo, et al.
Published: (2024-11-01)

Therapeutics in paediatric genetic diseases: current and future landscape
by: Ai Ling Koh, et al.
Published: (2023-01-01)

Targeting splicing for hematological malignancies therapy
by: Monika Szelest, et al.
Published: (2024-11-01)

KCTD17-mediated Ras stabilization promotes hepatocellular carcinoma progression
by: Young Hoon Jung, et al.
Published: (2024-10-01)

Efectividad del ejercicio terapéutico en la “Unified Huntington´s Disease Rating Scale” en pacientes diagnosticados de Enfermedad de Huntington (Effectiveness of therapeutic exercise on the “Unified Huntington´s Disease Rating Scale” in patients diagnosed with Huntington´s Disease)
by: Irimia Mollinedo Cardalda, et al.
Published: (2024-05-01)

Exploring non-coding variants and evaluation of antisense oligonucleotides for splicing redirection in Usher syndrome
by: Belén García-Bohórquez, et al.
Published: (2024-12-01)

Inhibiting the alternative pathway of complement by reducing systemic complement factor B: Randomized, double-blind, placebo-controlled phase 1 studies with Sefaxersen
by: Michael L. McCaleb, et al.
Published: (2025-03-01)

Safety and Efficacy of Nusinersen Focusing on Renal and Hematological Parameters in Spinal Muscular Atrophy
by: Hüseyin Bahadır Şenol, et al.
Published: (2025-01-01)

Golodirsen restores DMD transcript imbalance in Duchenne Muscular Dystrophy patient muscle cells
by: Rachele Rossi, et al.
Published: (2024-11-01)

Nucleic acid therapeutics: Past, present, and future
by: Sajid Naeem, et al.
Published: (2025-03-01)

The nexus of long noncoding RNAs, splicing factors, alternative splicing and their modulations
by: Pushkar Malakar, et al.
Published: (2024-12-01)

Orta Çağ’da Sistersiyen Ekonomisi Üzerine Bir Değerlendirme
by: Halil Yavaş
Published: (2021-10-01)

Amphiphilic Oligonucleotide Derivatives—Promising Tools for Therapeutics
by: Irina A. Bauer, et al.
Published: (2024-11-01)

Huntington’s disease modeling on HEK293 cell line
by: D. V. Sharipova, et al.
Published: (2017-12-01)

CAG Expansion in Androgen Receptor Gene of Infertile Men in Erbil Governorate
by: Dashne Abdulla Salih, et al.
Published: (2023-01-01)

RNA therapeutics in the clinic
by: Alexander Curreri, et al.
Published: (2023-01-01)

Functionalized oligonucleotides, synthetic catalysts as enzyme mimics
by: Chardet, Crystalle, et al.
Published: (2024-04-01)

Problems with the Care of a Patient with Huntington’s Disease Hospitalised in a Psychiatric Ward — Case Report
by: Katarzyna Gołębiewska, et al.
Published: (2020-06-01)

Malestar psicológico en portadores y no portadores de la mutación causante de enfermedad de Huntington y su relación con la carga de la enfermedad
by: Y. Rodríguez-Agudelo, et al.
Published: (2025-01-01)

Advances in Stem Cell Therapy for Huntington’s Disease: A Comprehensive Literature Review
by: Siddharth Shah, et al.
Published: (2025-01-01)